Failure of palatal shelf fusion results in cleft palate (CP) and may lead to malformation of palatal bones and undergrowth of the maxilla. It is not known whether defects in bone formation may contribute to this phenotype. We tested the hypothesis that impaired fusion of developing palatal shelves affects palatal bone development using palate organotypic cultures. Using two different approaches, we show that induction of cleft results in increased expression of pre-osteoblast and early osteoblast markers, Twist1, Snai1 and Runx2, and decreased expression of more mature markers of bone differentiation, collagen-1 and osteopontin, indicating delayed osteoblast differentiation in CPs. This, together with the increase in immature osteoblasts and proliferation observed in non-fused palatal shelves, suggests that palatal osteoblast differentiation is at least partly modulated by shelf fusion. Delayed osteoblast differentiation may therefore contribute to defects in gross morphology and function of the maxilla in CP patients.

Keywords:
Cleft palate, Osteoblast, Organ culture, Snai1, Mouse
1.
Bialek, P., B. Kern, X. Yang, M. Schrock, D. Sosic, N. Hong, et al (2004) A twist code determines the onset of osteoblast differentiation. Dev Cell 6: 423–435.
2.
Bloch-Zupan, A, N. Hunter, A. Manthey, J. Gibbins (2001) R-twist gene expression during rat palatogenesis. Int J Dev Biol 45: 397–404.
3.
Brunet, C.L., P.M. Sharpe, M.W. Ferguson (1995) Inhibition of TGF-β3 (but not TGF-β1 or TGF-β2) activity prevents normal mouse embryonic palate fusion. Int J Dev Biol 39: 345–355.
4.
Dahl, E., S. Kreiborg, B.L. Jensen, P. Fogh-Andersen (1982) Comparison of craniofacial morphology in infants with incomplete cleft lip and infants with isolated cleft palate. Cleft Palate J 19: 258–266.
5.
de Frutos, C.A., R. Dacquin, S. Vega, P. Jurdic, I. Machuca-Gayet, M.A. Nieto (2009) Snail1 controls bone mass by regulating Runx2 and VDR expression during osteoblast differentiation. EMBO J 28: 686–696.
6.
Diah, E., L.J. Lo, C.S. Huang, G. Sudjatmiko, I. Susanto, Y.R. Chen (2007) Maxillary growth of adult patients with unoperated cleft: answers to the debates. J Plast Reconstr Aesthet Surg 60: 407–413.
7.
Ducy, P., R. Zhang, V. Geoffroy, A.L. Ridall, G. Karsenty (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747–754.
8.
Fitzpatrick, D., F. Denhez, P. Kondaiah, R.J. Akhurst (1990) Differential expression of TGF-β isoforms in murine palatogenesis. Development 109: 585–595.
9.
Franci, C., M. Takkunen, N. Dave, F. Alameda, S. Gomez, R. Rodriguez, et al (2006) Expression of Snail protein in tumor-stroma interface. Oncogene 25: 5134–5144.
10.
Hermann, N.V., S. Kreiborg, T.A. Darvann, B.L. Jensen, E. Dahl, S. Bolund (2002) Early craniofacial morphology and growth in children with unoperated isolated cleft palate. Cleft Palate Craniofac J 39: 604–622.
11.
Hilliard, S.A., L. Yu, S.P. Gu, Z.Y. Zhang, Y.P. Chen (2005) Regional regulation of palatal growth and patterning along the anterior-posterior axis in mice. J Anat 207: 655–667.
12.
Kaartinen, V., J.W. Voncken, C. Shuler, D. Warburton, D. Bu, N. Heisterkamp, J. Groffen (1995) Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11: 415–421.
13.
Komori, T., H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, et al (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755–764.
14.
Lavrin, I.O., W. McLean, R.E. Seegmiller, B.R. Olsen, E.D. Hay (2001) The mechanism of palatal clefting in the Col11a1 mutant mouse. Arch Oral Biol 46: 865–869.
15.
Lee, M.S., G.N. Lowe, D.D. Strong, J.E. Wergedal, C.A. Glackin (1999) TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 75: 566–577.
16.
Martinez-Alvarez, C., M.J. Blanco, R. Pérez, M.A. Rabádan, M. Aparicio, E. Resel, et al (2004) Snail family members and cell survival in physiological and pathological cleft palates. Dev Biol 265: 207–218.
17.
McCance, A., D. Roberts-Harry, M. Sherriff, W.J. Houston (1993) Sri Lankan cleft lip and palate study model analysis: clefts of the secondary palate. Cleft Palate Craniofac J 30: 227–230.
18.
Miyake, T., A.M. Cameron, B.K. Hall (1997) Stage-specific expression patterns of alkaline phosphatase during development of the first arch skeleton in inbred C57BL/6 mouse embryos. J Anat 190(pt 2): 239–260.
19.
Murray, S.A., K.F. Oram, T. Gridley (2007) Multiple functions of Snail family genes during palate development in mice. Development 134: 1789–1797.
20.
Okano, J., S. Suzuki, K. Shiota (2006) Regional heterogeneity in the developing palate: morphological and molecular evidence for normal and abnormal palatogenesis. Congenit Anom (Kyoto) 46: 49–54.
21.
Opperman, L.A., A.A. Nolen, R.C. Ogle (1997) TGF-β1, TGF-β2 and TGF-β3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro. J Bone Miner Res 12: 301–310.
22.
Otto, F., A.P. Thornell, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, et al (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765–771.
23.
Pauws, E., A. Hoshino, L. Bentley, S. Prajapati, C. Keller, P. Hammond, et al (2009) Tbx22 null mice have a submucous cleft palate due to reduced palatal bone formation and also display ankyloglossia and choanal atresia phenotypes. Hum Mol Genet 18: 4171–4179.
24.
Proetzel, G., S.A. Pawlowski, M.V. Wiles, M. Yin, G.P. Boivin, P.N. Howles, et al (1995) Transforming growth factor-β3 is required for secondary palate fusion. Nat Genet 11: 409–414.
25.
Pungchanchaikul, P., A. Bloch-Zupan, P. Ferretti (2008) Snai1 expression in early osteogenesis, in vivo and in vitro. Genet Res Camb 90: 287.
26.
Pungchanchaikul, P., M. Gelbier, P. Ferretti, A. Bloch-Zupan (2005) Gene expression during palate fusion in vivo and in vitro. J Dent Res 84: 526–531.
27.
Rice, D.P. (2005) Craniofacial anomalies: from development to molecular pathogenesis. Curr Mol Med 5: 699–722.
28.
Rice, D.P., T. Aberg, ,Y.S. Chan, Z.Q. Tang, P.J. Kettunen, L. Pakarinen, et al (2000) Integration of FGF and TWIST in calvarial bone and suture development. Development 127: 1845–1855.
29.
Rice, R., I. Thesleff, D.P. Rice (2005) Regulation of Twist, Snail, and Id1 is conserved between the developing murine palate and tooth. Dev Dyn 234: 28–35.
30.
Swetloff, A., P. Ferretti (2005) Changes in E2F5 intracellular localization in mouse and human choroid plexus epithelium with development. Int J Dev Biol 49: 859–865.
31.
Taya, Y., S. O’Kane, M.W. Ferguson (1999) Pathogenesis of cleft palate in TGF-β3 knockout mice. Development 126: 3869–3879.
32.
ten Dijke, P., K.K. Iwata, C. Goddard, C. Pieler, E. Canalis, T.L. McCarthy, M. Centrella (1990) Recombinant transforming growth-factor type-β3: Biological activities and receptor-binding properties in isolated bone cells. Mol Cell Biol 10: 4473–4479.
33.
Yoshida, H., A. Nakamura, K. Michi, G.M. Wang, K. Liu, W.L. Qiu (1992) Cephalometric analysis of maxillofacial morphology in unoperated cleft palate patients. Cleft Palate Craniofac J 29: 419–424.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.